Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia

Chest

Volumn 128, Issue 3, 2005, Pages 1414-1422

  Deryke, C Andrew ^c   Lodise Jr , Thomas P ^d   Rybak, Michael J ^a   McKinnon, Peggy S ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c HARTFORD HOSPITAL   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bacteremia; Clinical outcomes; Critical care; Cross infection; Hospital mortality; ICU; Infection; Staphylococcal infections; Staphylococcal pneumonia; Ventilator associated pneumonia

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; LEVOFLOXACIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; COHORT ANALYSIS; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 24944576013     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1414     Document Type: Article

References (32)

1. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122:2183-2196
2. Lynch JP III. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119:373S-384S
3. Rello J, Diaz E. Pneumonia in the intensive care unit. Crit Care Med 2003; 31:2544-2551
4. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-1177
5. Gonzalez C, Rubio M, Romero-Vivas J, et al. Staphylococcus aureus bacteremic pneumonia: differences between community and nosocomial acquisition. Int J Infect Dis 2003; 7:102-108
6. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150: 1545-1549
7. Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786-792
8. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685
9. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200
10. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-420
11. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-394
12. Lodise TP, McKinnon PS, Swiderski L, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423
13. Sandiumenge A, Diaz E, Bodi M, et al. Therapy of ventilator-associated pneumonia: a patient-based approach based on the ten rules of "The Tarragona Strategy." Intensive Care Med 2003; 29:876-883
14. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481-1490
15. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-1797
16. Kollef MH, Rello J, Cammarata SK, et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-394
17. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement; American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-1725
18. Micek ST, Ward S, Fraser VJ, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125: 1791-1799
19. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412
20. Beck KD, Gastmeier P. Clinical or epidemiologic diagnosis of nosocomial pneumonia: is there any difference? Am J Infect Control 2003; 31:331-335
21. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383
23. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829
24. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Wayne, PA: National Committee for Clinical Laboratory Standards, 2004
25. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903
26. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24:655-661
27. Fagon J, Patrick H, Haas DW, et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin; Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161:753-762
28. Kaye MG, Fox MJ, Bartlett JG, et al. The clinical spectrum of Staphylococcus aureus pulmonary infection. Chest 1990; 97:788-792
29. Musher DM, Lamm N, Darouiche RO, et al. The current spectrum of Staphylococcus aureus infection in a tertiary care hospital. Medicine (Baltimore) 1994; 73:186-208
30. Iwahara T, Ichiyama S, Nada T, et al. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin- resistant Staphylococcus aureus. Chest 1994; 105:826-831
31. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674-680
32. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-1231